Alpha Teknova, Inc. (TKNO)
| Market Cap | 70.62M |
| Revenue (ttm) | 36.68M |
| Net Income (ttm) | -36.78M |
| Shares Out | 40.82M |
| EPS (ttm) | -1.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,745 |
| Open | 1.710 |
| Previous Close | 1.720 |
| Day's Range | 1.680 - 1.812 |
| 52-Week Range | 1.620 - 4.270 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 6.00 (+237.08%) |
| Earnings Date | May 8, 2024 |
About TKNO
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; ... [Read more]
Full Company ProfileFinancial Performance
In 2023, Alpha Teknova's revenue was $36.68 million, a decrease of -11.43% compared to the previous year's $41.42 million. Losses were -$36.78 million, -22.52% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TKNO stock is "Buy." The 12-month stock price forecast is $6.0, which is an increase of 237.08% from the latest price.
News
Teknova Reports Fourth Quarter and Full Year 2023 Financial Results
Full year 2023 total revenue was $36.7 million, down 11% year-over-year Achieved 36% annual growth in the number of Clinical Solutions customers in 2023 Company provides 2024 revenue guidance of $35-3...
Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
HOLLISTER, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Teknova Reports Third Quarter 2023 Financial Results
Raised $22.9 million of equity capital, paid down $10.0 million of long-term debt Third quarter 2023 total revenue was $8.2 million, down 24% from prior year Expect 2023 revenue at the low end of prev...
Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023
Teknova today announced that the Company will report its financial results for the third quarter on Thursday, November 9, 2023, following close of market.
Teknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development
Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV constr...
Teknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit Facility
HOLLISTER, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of no...
Teknova Reports Second Quarter 2023 Financial Results
Second quarter 2023 total revenue was $11.5 million, up 26% sequentially Received certification of new state-of-the-art facility for production of GMP-grade products Company revises 2023 revenue guida...
Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents
State-of-the-art facility in Hollister, California is designed to help bioprocessing and gene therapy companies scale from research to clinical production State-of-the-art facility in Hollister, Calif...
Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023
HOLLISTER, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Teknova Expands Proprietary AAV-Tek™ Solutions Product Line to Deliver End-to-End Solutions for Gene Therapy Process Development
First-of-its-kind screening kit now available for AAV8 – along with a suite of high-quality reagents to support the entire AAV workflow – helping gene therapy developers save months in process develop...
Teknova to Participate in Upcoming Investor Conference
HOLLISTER, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercializat...
Teknova Reports First Quarter 2023 Financial Results
First quarter 2023 total revenue was $9.1 million, up 16% sequentially Launch of proprietary AAV-Tek™ Solutions gene therapy product line Company reaffirms 2023 revenue guidance of $42-46 million HOL...
Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting
Company will share their latest findings for custom product innovations aimed at addressing key gene therapy bioprocessing bottlenecks Company will share their latest findings for custom product innov...
Teknova to Report First Quarter 2023 Financial Results on May 10, 2023
HOLLISTER, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercializ...
Teknova Reports Fourth Quarter and Full Year 2022 Financial Results
Full year 2022 total revenue was $41.4 million, up 12% year-over-year New, state-of-the-art manufacturing facility now operational Company provides 2023 revenue guidance of $42-46 million
Teknova and Sartorius BIA Separations Announce Collaboration to Address Critical Pain Point in Gene Therapy Process Development
An AAV chromatography platform plus optimized custom buffer formulations yields a state-of-the-art offering for increased AAV recovery An AAV chromatography platform plus optimized custom buffer formu...
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Teknova to Participate in Upcoming Investor Conferences
HOLLISTER, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercializa...
Teknova Reports Third Quarter 2022 Financial Results
Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year Company updates 2022 revenue outlook to $40-42 million Cash position of $50 million supports path to profitability
Teknova to Report Third Quarter 2022 Financial Results on November 9, 2022
HOLLISTER, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of dr...
Teknova Reports Second Quarter 2022 Financial Results
Second quarter 2022 total revenue was $11.7 million, up 41% year-over-year Cash position of $64.7 million supports ongoing investment in growth strategy Company updates 2022 revenue outlook to $38-42 ...
Teknova to Report Second Quarter 2022 Financial Results on August 10, 2022
HOLLISTER, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of dr...
Teknova Reports First Quarter 2022 Financial Results
First quarter 2022 total revenue was $11.1 million, up 23% year-over-year Excluding Sample Transport revenue, first quarter 2022 total revenue was $11.1 million, up 37% year-over-year Strong cash posi...
Teknova to Report First Quarter 2022 Financial Results on May 11, 2022
HOLLISTER, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of dru...
Teknova Reports Fourth Quarter and Full Year 2021 Financial Results
Full year 2021 total revenue was $36.9 million, up 18% year-over-year Excluding Sample Transport revenue of $1.5 million, full year 2021 total revenue was $35.4 million, up 31% year-over-year Company ...